Digital Health Global
AUGUST 15, 2023
–(BUSINESS WIRE)– #Biotech –Taking a people-first approach, BioscienceLA, the ecosystem accelerator for life sciences in Greater Los Angeles, has launched its inaugural Leadership Catalyst Program for trailblazers in biotechnology and related sectors. We are delighted to be part of this impactful program.”
Digital Health Global
SEPTEMBER 27, 2023
Our mission is to accelerate the commercialization of breakthrough innovations like the AUTAC platform for health impact, and we welcome Automera and ALSP to Singapore’s growing life sciences translational community.” Together, we advance Singapore as a global life sciences translational hub.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Health Populi
APRIL 26, 2022
The press release lists the names of each of the 47 individual pharma companies assessed, such as Big Pharma leaders like AstraZeneca, Bayer, Bristol Myers Squibb, GSK, Merck, Novartis, and Pfizer, along with companies associated with biotech like Amgen, Biogen, Genentech, and Gilead. Generics such as Mylan and Teva, among others.
Society for Participatory Medicine
JANUARY 27, 2022
Healthcare stakeholders such as health systems, pharmaceutical companies, biotech and life sciences firms, and insurance companies serve patients as end users. And I propose a toast: “To stop talking about involving patients and actually do it in 2022. Connect with her at [link]. Did you enjoy this post?
Digital Health Global
APRIL 3, 2023
Hyman, MD, Director, Stanley Center for Psychiatric Research at the Broad Institute and Co-Chair of the Wyss Center Executive Board: “Erwin is a pioneer in life science research and a visionary and experienced leader in translating promising technologies to improve patient care. Professor Steven E.
Digital Health Global
DECEMBER 5, 2023
This infusion of capital, supported by new investor Bpifrance (through its InnoBio 2 fund), and existing backers Khosla Ventures and Seventure Partners (with Health For Life Capital ), propels Eligo towards becoming a clinical-stage biotech. Concurrent with this financing, Laia Crespo, Ph.D., Partner at Sanofi Ventures.
Lloyd Price
SEPTEMBER 2, 2023
Exec Summary: The European HealthTech M&A market is expected to remain active in 2023, albeit with some slowdown from the record-breaking levels seen in 2022. This growth is expected to create opportunities for M&A activity, as pharmaceutical companies look to acquire smaller, innovative biotech companies.
Expert insights. Personalized for you.
88 
Let's personalize your content